Debt-to-equity of Transcode Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Transcode Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Transcode Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 114%, a 12% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Transcode Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 114% -16% -12% 30 Sep 2025
Q2 2025 103% -26% -20% 30 Jun 2025
Q1 2025 160% +36% +29% 31 Mar 2025
Q4 2024 321% +83% +35% 31 Dec 2024
Q3 2024 131% -76% -37% 30 Sep 2024
Q2 2024 130% -3.4% -2.6% 30 Jun 2024
Q1 2024 124% +58% +87% 31 Mar 2024
Q4 2023 239% +210% +735% 31 Dec 2023
Q3 2023 207% +190% +1117% 30 Sep 2023
Q2 2023 133% +122% +1067% 30 Jun 2023
Q1 2023 66% +43% +180% 31 Mar 2023
Q4 2022 29% 31 Dec 2022
Q3 2022 17% 30 Sep 2022
Q2 2022 11% 30 Jun 2022
Q1 2022 24% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.